1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab plus Pertuzumab|DRUG: Hormonal Therapy with Anastrozole and Fulvestrant|DRUG: Chemotherapy with Eribulin
Sponsor: University of Maryland, Baltimore
Collaborators: Genentech, Inc.